lyp in 1

LYP-IN-1 is a powerful LYP inhibitor that demonstrates high potency, selectivity, and specificity, with a Ki of 110 nM and an IC 50 of 0.259 μM. Beyond its primary target, LYP-IN-1 also exhibits selectivity towards a wide range of PTPs, including SHP1 (IC 50 = 5 μM) and SHP2 (IC 50 = 2.5 μM). Additionally, LYP-IN-1 demonstrates remarkable efficacy in T- and mast cells, making it a valuable tool for investigating autoimmune disorders.

LyP-1 acetate is a tumor homing peptide specifically binding to p32 receptors overexpressed in various tumor-associated cells.

LyP-1 is a cyclic peptide comprised of 9 amino acids, designed to target and bind selectively to p32 receptors that are overexpressed in a range of tumor-associated cells.

LyP-1 TFA, a cyclic nine-amino-acid peptide, exhibits selective binding to p32 receptors, which are overexpressed in a variety of tumor-associated cells [1].

LYP-IN-3 (compound D34) is a selective Lymphoid-tyrosine phosphatase (LYP) inhibitor (Ki=0.93 μM) that modulates the T-cell receptor (TCR) signaling pathway during tumor progression. It promotes T-cell activation, hinders M2 macrophage polarization, and increases PD-1 PD-L1 expression. When combined with PD-1 PD-L1 inhibitors, LYP-IN-3 may enhance cancer immunotherapy [1].

LTV-1 has the potential for autoimmunity treatment. LTV-1 is a potent lymphoid tyrosine phosphatase (LYP) inhibitor in T cells with an IC50 of 508 nM.

LYP-IN-4 (compound D14), a reversible and selective lymphotyrosine phosphatase (LYP) inhibitor (Ki=1.34 μM, IC50=3.52μM), regulates TCR signaling, increases PD-1 PD-L1 expression, and strengthens anti-tumor immunity. It also stimulates T cell activation, impedes M2 macrophage polarization, and suppresses tumor progression in MC38 isogenic mouse models.